Terms: = Small Cell Lung Cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Prognosis
1295 results:
1. Nephrotoxicity of targeted therapy used to treat lung cancer.
Li Q; Lin J; Hao G; Xie A; Liu S; Tang B
Front Immunol; 2024; 15():1369118. PubMed ID: 39026680
[TBL] [Abstract] [Full Text] [Related]
2. A Review of the Molecular Determinants of Therapeutic Response in Non-small cell lung cancer Brain Metastases.
Boldig C; Boldig K; Mokhtari S; Etame AB
Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000069
[TBL] [Abstract] [Full Text] [Related]
3. RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression.
Huang S; Zhang J; Wu X; Liang B; Pang N; Yang L; Zhang Z
Life Sci; 2024 Aug; 351():122849. PubMed ID: 38897346
[TBL] [Abstract] [Full Text] [Related]
4. Evaluating the Clinical Characteristics and prognosis of Advanced Non-small cell lung cancer with Exon 20 Insertions.
Wang H; Xu Y; Lin J; Huang Y
Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
[TBL] [Abstract] [Full Text] [Related]
5. SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors' therapeutic implication.
Pang LL; Zhou HQ; Zhang YX; Zhuang WT; Pang F; Chen LJ; Liao J; Huang YH; Mao TQ; Mai ZH; Zhang L; Fang WF
ESMO Open; 2024 Jun; 9(6):103472. PubMed ID: 38833972
[TBL] [Abstract] [Full Text] [Related]
6. The clinicopathological features and possible physiological mechanisms of only the egfr-T790M primary mutation in patients with lung adenocarcinoma.
Zhao P; Xu L; Zhu H; Ding W; Tang H
Pathol Res Pract; 2024 Jul; 259():155352. PubMed ID: 38781763
[TBL] [Abstract] [Full Text] [Related]
7. Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-small cell lung Carcinoma with or without Alterations in Oncogenic Drivers.
Somme LB; Chouaid C; Moinard-Butot F; Barbe-Richaud JB; Greillier L; Schott R
BioDrugs; 2024 Jul; 38(4):487-497. PubMed ID: 38767823
[TBL] [Abstract] [Full Text] [Related]
8. The real-world treatment characteristic and efficacy of immune checkpoint inhibitors in non-small cell lung cancer: Data from a retrospective cohort study.
Zhang C; Shao J; Tang X; Wu J; Li P; Li W; Wang C
Int Immunopharmacol; 2024 Jun; 134():112152. PubMed ID: 38761777
[TBL] [Abstract] [Full Text] [Related]
9. Clinical Outcomes of Patients with Non-small cell lung cancer Leptomeningeal Disease Following Receipt of egfr-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone.
Mills MN; Uno A; Li P; Liveringhouse C; Kim Y; Oliver DE; Perez BA; Creelan BC; Yu M; Forsyth PA; Pina Y; Ahmed KA
Clin Lung Cancer; 2024 Jul; 25(5):417-423.e1. PubMed ID: 38719648
[TBL] [Abstract] [Full Text] [Related]
10. Brain Metastasis from egfr-Mutated Non-small cell lung cancer: Secretion of IL11 from Astrocytes Up-Regulates PDL1 and Promotes Immune Escape.
Tang M; Xu M; Wang J; Liu Y; Liang K; Jin Y; Duan W; Xia S; Li G; Chu H; Liu W; Wang Q
Adv Sci (Weinh); 2024 Jul; 11(26):e2306348. PubMed ID: 38696655
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
12. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
Han R; Guo H; Shi J; Zhao S; Jia Y; Liu X; Liu Y; Cheng L; Zhao C; Li X; Zhou C
BMC Med; 2024 Apr; 22(1):174. PubMed ID: 38658988
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
[TBL] [Abstract] [Full Text] [Related]
14. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract] [Full Text] [Related]
15. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells.
Fonseca P; Cui W; Struyf N; Tong L; Chaurasiya A; Casagrande F; Zhao H; Fernando D; Chen X; Tobin NP; Seashore-Ludlow B; Lundqvist A; Hartman J; Göndör A; Östling P; Holmgren L
J Exp Clin Cancer Res; 2024 Apr; 43(1):107. PubMed ID: 38594748
[TBL] [Abstract] [Full Text] [Related]
16. DRD1 suppresses cell proliferation and reduces egfr activation and PD-L1 expression in NSCLC.
Grant CE; Flis AL; Toulabi L; Zingone A; Rossi E; Aploks K; Sheppard H; Ryan BM
Mol Oncol; 2024 Jun; 18(6):1631-1648. PubMed ID: 38572507
[TBL] [Abstract] [Full Text] [Related]
17. Association of systemic inflammatory markers with prognosis in erlotinib-treated egfr-mutant non-small cell lung cancer.
Yetişir AE; Paydaş S; Büyükşimşek M; Oğul A; Kolsuz İ; Kıdı MM
J Cancer Res Ther; 2024 Jan; 20(1):285-288. PubMed ID: 38554335
[TBL] [Abstract] [Full Text] [Related]
18. Clinical Management of Patients with Non-small cell lung cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.
Khasraw M; Yalamanchili P; Santhanagopal A; Wu C; Salas M; Meng J; Karnoub M; Esker S; Felip E
Adv Ther; 2024 May; 41(5):1815-1842. PubMed ID: 38509433
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report.
Tomic K; Krpina K; Baticic L; Samarzija M; Vranic S
J Drug Target; 2024 Jun; 32(5):499-509. PubMed ID: 38506620
[TBL] [Abstract] [Full Text] [Related]
20. [Improved Outcomes in Resectable Advanced or Recurrent lung cancer].
Goto Y
Gan To Kagaku Ryoho; 2024 Mar; 51(3):237-239. PubMed ID: 38494799
[TBL] [Abstract] [Full Text] [Related]
[Next]
